Australian Clinical Labs Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Australian Clinical Labs ha un patrimonio netto totale di A$177.8M e un debito totale di A$55.1M, che porta il suo rapporto debito/patrimonio netto a 31%. Le sue attività totali e le sue passività totali sono rispettivamente A$593.1M e A$415.3M. L'EBIT di Australian Clinical Labs è A$62.6M rendendo il suo rapporto di copertura degli interessi 3.8. Ha liquidità e investimenti a breve termine pari a A$26.8M.

Informazioni chiave

31.0%

Rapporto debito/patrimonio netto

AU$55.06m

Debito

Indice di copertura degli interessi	3.8x
Contanti	AU$26.85m
Patrimonio netto	AU$177.77m
Totale passività	AU$415.30m
Totale attività	AU$593.06m

Aggiornamenti recenti sulla salute finanziaria

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Jun 20

Recent updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { ACL di A$133.6M ) non coprono le sue passività a breve termine ( A$207.7M ).

Passività a lungo termine: Le attività a breve termine di ACL ( A$133.6M ) non coprono le sue passività a lungo termine ( A$207.6M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 15.9% ) di ACL è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di ACL si è ridotto da 204.2% a 31% negli ultimi 5 anni.

Copertura del debito: Il debito di ACL è ben coperto dal flusso di cassa operativo ( 289.8% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di ACL sono ben coperti dall'EBIT ( 3.8 x copertura).

Australian Clinical Labs Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane